Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Til expansion from fine needle aspirates and small biopsies

A biopsy, IL-2 technology, applied in cell culture active agents, biochemical equipment and methods, microorganisms, etc., can solve problems such as the limitation of obtaining TIL

Pending Publication Date: 2020-08-28
IOVANCE BIOTHERAPEUTICS INC
View PDF168 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Current TIL production process is limited by how TIL is obtained from patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Til expansion from fine needle aspirates and small biopsies
  • Til expansion from fine needle aspirates and small biopsies
  • Til expansion from fine needle aspirates and small biopsies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[1817] Example 1: Preparation of medium for PREP and REP processes

[1818] This example describes the procedure for preparing tissue culture medium for use in protocols involving the culture of tumor infiltrating lymphocytes (TILs) derived from a variety of tumor types including, but not limited to, metastatic melanoma, Head and neck squamous cell carcinoma (HNSCC), ovarian cancer, triple negative breast cancer and lung adenocarcinoma. This medium can be used to prepare any of the TILs described in this application and in the Examples.

[1819] Preparation of CM1

[1820] Remove the following reagents from refrigeration and warm them in a 37°C water bath: (RPMI1640, human AB serum, 200mML-glutamine). Prepare CM1 medium according to Table 32 below by adding each ingredient to the top of a 0.2 μm filter unit appropriate for the volume to be filtered. Store at 4°C.

[1821] Table 32: Preparation of CM1

[1822] Element final concentration Final volume 500mL ...

Embodiment 2

[1833] Example 2: Use of IL-2, IL-15 and IL-21 Cytokines Mixture

[1834] This example describes the use of IL-2, IL-15 and IL-21 cytokines as additional T cell growth in combination with the TIL method of the example factor.

[1835] Using the methods described herein, TILs were grown from colorectal, melanoma, cervical, triple-negative breast, lung, and kidney tumors in the presence of IL-2 in one experimental arm; and, in the other In one arm, IL-2 was replaced with a combination of IL-2, IL-15 and IL-21 at the beginning of the culture. At the completion of pre-REP, cultures were assessed for expansion, phenotype, function (CD107a+ and IFNγ) and TCR Vβ repertoire (TCR Vβ repertoire). IL-15 and IL-21 are described elsewhere herein and Gruijl et al., IL-21 promotes the expansion of CD27+CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells (IL-21 promotes CD27+CD28+ tumor infiltrating lymphocytes Expansion of ...

Embodiment 3

[1837] Example 3: Qualified individual batches of gamma-irradiated peripheral mononuclear cells

[1838] This example describes a novel, simplified procedure for qualifying individual batches of gamma-irradiated peripheral mononuclear cells (PBMC, also known as MNC) for use as isotypes in the exemplary methods described herein. Allogeneic feeder cells.

[1839] Each batch of irradiated MNC feeder cells was prepared from a single donor. Each lot or donor was screened individually for the ability to expand TILs in REPs in the presence of purified anti-CD3 (clone OKT3) antibodies and interleukin 2 (IL-2). Additionally, each batch of feeder cells was tested without the addition of TIL to verify that the dose of gamma radiation received was sufficient to render them replicatively incompetent.

[1840] background

[1841] REP of TILs requires gamma-irradiated growth-arrested MNC feeder cells. Membrane receptors on feeder MNCs bind to anti-CD3 (clone OKT3) antibodies and crosslin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present disclosure provides methods for expanding TIL populations from fine needle aspirates (FN As) or small biopsies which contain low numbers of TILs, using the methods disclosed herein including in a closed system that leads to improved phenotype and increased metabolic health of the TILs in a shorter time period.

Description

[0001] related application [0002] This application claims U.S. Provisional Patent Application No. 62 / 588,044, filed November 17, 2017, U.S. Provisional Patent Application No. 62 / 621,515, filed January 24, 2018, and U.S. Provisional Patent Application No. 62 / 621,515, filed November 5, 2018. Priority to Provisional Patent Application Serial No. 62 / 756,038, the entire contents of which are hereby incorporated by reference in their entirety. Background technique [0003] The use of adoptively transferred tumor-infiltrating lymphocytes (TILs) for the treatment of large, refractory cancers represents an effective approach for treating patients with poor prognosis. Gattinoni et al., Nat. Rev. Immunol., 2006, 6, 383-393. Successful immunotherapy requires large numbers of TILs, and commercialization requires robust and reliable methods. This is a challenge to achieve due to technical, logistical and regulatory issues of cell expansion. Due to its speed and efficiency, IL-2-based T...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0783A61P35/00A61K35/17A61K39/00
CPCC12N5/0636C12N2501/2302C12N2501/2315C12N2501/2321C12N2501/515C12N2501/599C12N2502/11A61K2039/892A61K2039/876A61K2039/852A61K2039/86A61K39/4644A61K2239/54A61K39/4611A61K2239/57A61K2239/55A61K2239/59A61K35/17A61K39/0011
Inventor M·辛普森-埃布尔森C·夏尔提-考多
Owner IOVANCE BIOTHERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com